Who is sponsoring FIN-SGLT2-HF?

FIN-SGLT2-HF is sponsored by Mansoura University.

What condition does FIN-SGLT2-HF study?

FIN-SGLT2-HF studies Heart Failure.

What drugs are being tested in FIN-SGLT2-HF?

Interventions: Finerenone, dapagliflozine.

What is the status of FIN-SGLT2-HF?

FIN-SGLT2-HF is currently NOT_YET_RECRUITING.

Last reviewed 2026-01-20 · How we verify

Finerenone Plus SGLT2 Inhibitors in Heart Failure (FIN-SGLT2-HF)

NCT07351864 PHASE4 NOT_YET_RECRUITING

The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.

Details

Lead sponsor	Mansoura University
Phase	PHASE4
Status	NOT_YET_RECRUITING
Enrolment	60
Start date	Sun Jan 18 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Heart Failure

Interventions

Finerenone
dapagliflozine

Countries

Egypt